Therapeutic efficacy and safety of chemotherapy subsequent EGFR-TKi in advanced non-small cell lung cancer patients with EGFR-TKi acquired resistance
Li, J.; Hong, Q.; Zhang, X.; Hu, J.; Bai, C.
Zhonghua Yi Xue Za Zhi 94(30): 2342-2345
2014
ISSN/ISBN: 0376-2491 PMID: 25399974 Document Number: 676808
To explore the therapeutic efficacy and safety of chemotherapy subsequent epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in advanced non-small cell lung cancer (NSCLC) patients with EGFR-TKI acquired resistance. The clinical features of 36 advanced NSCLC patients with EGFR-TKI acquired resistance from Affiliated Zhongshan Hospital, Fudan University between May 2006 and April 2014 were retrospectively reviewed. Twenty-seven of them received chemotherapy subsequent EGFR-TKI and another 9 chemotherapy alone. The short-term response, progression-free survival and side effects of two groups were compared. The objective response rates of chemotherapy subsequent EGFR-TKI and chemotherapy alone groups were 7.4% and 0 (P = 0.557), disease control rates 81.5% and 44.4% (P = 0.046) and median progression-free survival 3.3 and 2.5 months, respectively (P = 0.587). No significant differences existed in the rates of side effects between two groups (P > 0.05). The disease control rates of chemotherapy subsequent EGFR-TKI group are higher than chemotherapy alone group, but there is no survival benefit. And the side effects of subsequent therapy are tolerable.